期刊
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
卷 143, 期 5, 页码 2413-2422出版社
AMER CHEMICAL SOC
DOI: 10.1021/jacs.0c12851
关键词
-
资金
- Fundamental Research Funds for the Central Universities [11170042105, buctrc202004]
- National Natural Science Foundation of China [21502195]
- Natural Science Foundation [31630027, 32030060, 31630026]
- NSFC [51861135103]
- NSFC-DFG [31761133013]
- Chinese Academy of Sciences [XDA09030301]
- Special Key Project of Technological Innovation, and Application Development in Chongqing [cstc2019jscx-dxwtBX0004]
- National Creative Research Initiative programs of the National Research Foundation of Korea (NRF) - Korean government (MSIP) [2012R1A3A2048814]
This study developed a novel reversible photodynamic therapy switch for controlling the production of singlet oxygen, providing a potential strategy for photodynamic-immunotherapy.
The development of activatable photosensitizers to allow for the reversible control of singlet oxygen (O-1(2)) production for photodynamic therapy (PDT) faces great challenges. Fortunately, the flourishing field of supramolecular biotechnology provides more effective strategies for activatable PDT systems. Here, we developed a new reversible PDT on a switch that controls the O-1(2) generation of self-assembled albumin nanotheranostics in vitro and in vivo. A new molecular design principle of aggregation-induced self-quenching photochromism and albumin on-photoswitching was demonstrated using a new asymmetric, synthetic diarylethene moiety DIA. The photosensitizer porphyrin and DIA were incorporated as building blocks in a glutaraldehyde-induced covalent albumin cross-linking nanoplatform, HSA-DIA-porphyrin nanoparticles (NPs). More importantly, the excellent photoswitching property of DIA enables the resultant nanoplatform to act as a facile, switchable strategy for photodynamic-immunotherapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据